MARKET

OGEN

OGEN

ORAGENICS
AMEX

Real-time Quotes | Nasdaq Last Sale

0.3941
+0.0081
+2.10%
After Hours: 0.4035 +0.0094 +2.39% 19:13 11/25 EST
OPEN
0.3900
PREV CLOSE
0.3860
HIGH
0.4150
LOW
0.3900
VOLUME
4.47M
TURNOVER
--
52 WEEK HIGH
2.090
52 WEEK LOW
0.3600
MARKET CAP
24.04M
P/E (TTM)
-0.7851
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
Business Wire · 2d ago
Mid-Afternoon Market Update: Dow Drops Over 100 Points; Mesoblast Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.46% to 29,346.95 while the NASDAQ rose 0.14% to 11,920.95. The S&P also fell, dropping 0.20% to 3,574.82.
Benzinga · 6d ago
Mid-Day Market Update: Nasdaq Edges Higher; Nano Dimension Shares Plunge
Midway through trading Friday, the Dow traded down 0.43% to 29,355.69 while the NASDAQ rose 0.14% to 11,921.21. The S&P also fell, dropping 0.24% to 3,573.32.
Benzinga · 6d ago
Oragenics shares drop 28% after pricing $5.25M stock offering
Oragenics (OGEN) plunges 28% premarket after pricing its public offering of ~14.2M common shares at $0.37/share, for expected gross proceeds of ~$5.25M.Underwriters' over-allotment is an additional 2,128,378 shares. Net proceeds will be used
Seekingalpha · 6d ago
Oragenics Prices $5.25M Offering Of 14.189M Shares At $0.37/Share
Oragenics Prices $5.25 Million Common Stock Offering Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a company focused on the creation of the Terra CoV-2 vaccine candidate to combat
Benzinga · 6d ago
Oragenics Prices $5.25 Million Common Stock Offering
ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING
Business Wire · 6d ago
CORRECTING AND REPLACING Oragenics Announces Proposed Underwritten Public Offering
Oragenics Announces Proposed Underwritten Public Offering
Business Wire · 6d ago
Oragenics launches equity offering
Oragenics (OGEN) down 1% AH, has commenced a proposed underwritten public offering of common stock.Volume, price are yet to be determined.
Seekingalpha · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OGEN. Analyze the recent business situations of ORAGENICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OGEN stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 18
Institutional Holdings: 6.33M
% Owned: 10.37%
Shares Outstanding: 61.00M
TypeInstitutionsShares
Increased
4
857.31K
New
5
128.78K
Decreased
2
2.71M
Sold Out
2
2.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Director
Frederick Telling
President/Chief Executive Officer/Director
Alan Joslyn
Chief Financial Officer/Treasurer/Secretary
Michael Sullivan
Director
Kim Murphy
Independent Director
Alan Dunton
Independent Director
Robert Koski
Independent Director
Charles Pope
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OGEN
Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oragenics Inc stock information, including AMEX:OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.